Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions

BACKGROUND: Sorafenib is an orally administered multikinase inhibitor with antiangiogenic and antiproliferative properties. The results of large clinical trials demonstrate that sorafenib prolongs survival and the time to progression of patients with advanced hepatocellular carcinoma (HCC). The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sae Hwan, Song, Il Han, Noh, Ran, Kang, Ha Yan, Kim, Suk Bae, Ko, Soon Young, Lee, Eoum Seok, Kim, Seok Hyun, Lee, Byung Seok, Kim, An Na, Chae, Hee Bok, Kim, Hong Soo, Lee, Tae Hee, Kang, Young Woo, Lee, Jae Dong, Lee, Heon Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403976/
https://www.ncbi.nlm.nih.gov/pubmed/25885683
http://dx.doi.org/10.1186/s12885-015-1273-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403976/
https://www.ncbi.nlm.nih.gov/pubmed/25885683
http://dx.doi.org/10.1186/s12885-015-1273-2

Ejemplares similares